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Abstract 
Purpose: To evaluate knowledge, attitude and practice (KAP) of pharmacovigilance (PV) and adverse 
drug reactions (ADRs) reporting among community and hospital pharmacists in Abia and Imo States of 
Nigeria. 
Methods: A cross-sectional survey was done using a validated questionnaire distributed among 
hospital and community pharmacists in the two States. 
Results: Out of the 227 copies of the questionnaire administered, 169 (74.4%) were usable. Only 22% 
of all the pharmacists had postgraduate qualification but 78.0% had more than five years post-
qualification experience. All respondents were aware of the concept of PV; 73.4% had seen a patient 
with ADR while 17.7% had not seen the ADR reporting form in use in Nigeria. Only 24.3% had officially 
reported an ADR. Factors that affected reporting were lack of incentive (52.1%), role conflict (69.2%), 
and role overload (72.8%). Mean score for KAP-related questions was higher among hospital 
pharmacists than their community counterparts.  
Conclusion: The study has shown that while all pharmacists were aware of PV, the attitude and 
practice of many of them constituted a challenge and accounted for poor level of reporting.  
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Adverse drug reactions (ADRs) rank among the 
leading causes of death in many countries [1-3]. 
The annual health bills arising from drug-related 
adverse events have been estimated to be very 
high [4,5]. For example the estimated cost of 
drug related morbidity and mortality in the United 
States was $US177.4 billion in the year 2000 [6]. 
The Nigerian drug safety scenario is worse than 
what obtains in developed countries because of 
widespread irrational use of medicines [7,8]. In 
addition, the presence of unregulated drug 
markets, weak regulatory systems, lack of 
enforcement of the regulations, and inadequate 
resources to monitor safety of medicines [9] are 
major issues in Nigeria. 
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Pharmacists have been recognized as very 
easily accessible health professionals [10,11] 
and their core competence of being experts in 
drugs puts them in a good position to assist in 
promoting the concept of pharmacovigilance. 
The community and hospital pharmacists directly 
relate with patients much more than their 
counterparts in the industry, regulatory agencies 
and the academia [11]. They are therefore very 
relevant in pharmacovigilance. 
 
Spontaneous reporting of adverse drug reactions 
has been acknowledged as the cornerstone of 
pharmacovigilance [12]. It is a system in which 
case reports of adverse drug events are 
voluntarily submitted by health professionals and 
subjects to the National Pharmacovigilance 
Centre [13]. Its success depends on the 
awareness, motivation and enthusiasm of 
healthcare practitioners [12,14]. Reporting of 
ADR is voluntary and the number of reports per 
year is often low thereby leading to the 
suggestion that it should be mandatory but this 
has always been opposed by health workers 
because they view it as an extra burden on their 
busy schedules [15]. Because of their specialized 
skills, community and hospital pharmacists, help 
to establish and strengthen pharmacovigilance 
structures in their places of practice through 
spontaneous reporting as has been observed in 
Canada [12]. 
 
Nigeria falls far below the recommended 200 
reports per million population per year [7]. Many 
reactions to drugs are often not recognized and 
even when they are recognized, they are not 
reported [16]. None of the very few studies in 
respect of pharmacovigilance in Nigeria has 
comparatively evaluated the knowledge, attitude 
and practice of pharmacovigilance (KAP) by 
community and hospital pharmacists [17-20]. In 
this study, we assessed KAP of PV and ADR 
reporting in two contiguous States in the Federal 
Republic of Nigeria in the belief that the data 
would help in providing some information that 




Study design and setting 
 
The study was a descriptive cross-sectional 
survey carried out to evaluate the knowledge, 
attitude and practice of pharmacovigilance by 
community and hospital pharmacists in Abia and 
Imo States of South-Eastern Nigeria.  
 
Available records from the Office of Directorate 
of Pharmaceutical Services of Abia and Imo 
States showed that there were altogether, 115 
community pharmacists and 112 pharmacists 
employed in the hospitals. According to the 2006 
national census, the two states have a total 
population of approximately 7 million. This gives 
a pharmacist: population ratio of 1:25,000. Each 
State had two tertiary hospitals for the training of 
medical doctors and other healthcare 
professionals; secondary health facilities and 
several privately owned pharmacies. In each of 
the States, there was a Federal Government of 
Nigeria owned tertiary health facility and an ADR 
Monitoring or Drug Safety Committee that was 
responsible for receiving cases of ADRs and 
forwarding confirmed cases to the National 





A 34-point pre-designed questionnaire was used 
for the study. The questionnaire was adapted 
from previous studies on knowledge, attitude, 
and practice of healthcare professionals and 
ADR-reporting [21,22] using both open and 
closed ended questions. Some modifications 
were made to the questionnaire to reflect policies 
and guidelines in Nigeria. Face validity and 
internal consistency were tested through a pilot 
study of 20 randomly selected pharmacists (n 
=10 each for hospital and community) and 
adjustments were made where necessary. Total 
possible score on the knowledge items was 24 (1 
point per item). The maximum total score on the 
attitude items was 14 while the maximum total 
score on the practice items was 18. Correct 
responses to questions on knowledge, attitude 
and practice were graded: 0-49% (poor); 50-59% 




In the case of the hospital pharmacists, 
distribution of the questionnaire was facilitated by 
the Heads of Department of Pharmacy at the 
various study sites. Distribution of the 
questionnaire among community pharmacists 
was done on a one-on-one basis after obtaining 
verbal consent from the respondents. Similarly, 
consent to participate was sought among 
hospital pharmacists through a brief explanatory 
speech delivered by the investigators at each of 
the study sites. The questionnaire was self-





Data were entered into Microsoft Excel software 
(2007) and then SPSS version 11.0 (SPSS, Inc. 
Chicago, IL) and double-checked to ensure 
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accuracy. All data are presented as simple 




Demographics of participants 
 
Basic demographics of respondents are 
presented in Table 1. Out of the 227 copies of 
the questionnaire administered, 184 were 
returned out of which 169 (74.4%) were properly 
completed and usable. Majority of them were 
less than 40 years of age and had no 
postgraduate education. Percentage of retuned 
but usable questionnaire was 54.5 and 93.9 for 
community and hospital pharmacists 
respectively. 
 
Most community pharmacists (70.5%) and 
hospital pharmacists (82.4%) had only the 
minimum qualification (B.Sc, B.Pharm, PharmD) 
needed to practice. The remainders had 
additional relevant postgraduate qualifications 
(M.Sc, M.Pharm, and Fellowship of the West 
African Postgraduate College of Pharmacy). 
 
The percentages of pharmacists with more than 
five years of experience were 60.7% of all 
community pharmacists, 88.0% of all hospital 




Knowledge of pharmacovigilance by 
pharmacists 
 
All respondent pharmacists were aware of the 
term pharmacovigilance (Table 2). This high level 
of awareness did not translate to good 
knowledge of pharmacovigilance. For example, 
among community pharmacists, only 41.0% 
knew that cohort event monitoring (CEM) was a 
type of active pharmacovigilance while only 
24.9% of all pharmacists were aware of the 
national ADR reporting form (yellow form). 
Altogether, only 20.1% of all respondents had 
received training in pharmacovigilance. 
Pharmacists who could define 
pharmacovigilance correctly comprised of 52.5% 
(community), 73.1% (hospital), and 65.7% (all). 
 
Attitude of pharmacists towards pharmaco-
vigilance 
 
Figures 1 – 3 show the attitude of pharmacists 
towards pharmacovigilance. In general, not all 
pharmacists who participated in the study agreed 
that it was necessary to report ADRs (Figure 1). 
Similarly, 78.7% of community pharmacists and 
79.6% of hospital pharmacists considered it 
important that pharmacy undergraduates should 
be trained on pharmacovigilance. Only 47.5% of 
community pharmacists agreed that ADR 
reporting should be mandatory for pharmacists. 
In contrast, 72.0% of hospital pharmacists 
agreed that ADR reporting should be mandatory 
for pharmacists. 
 










State of Practice    
Abia 21 (34.4) 43 (39.8) 64 (37.9) 
Imo  40 (65.6) 65 (60.2) 105 (62.1) 
Gender    
Male 39 (63.9) 58 (53.7) 97 (57.4) 
Female 22 (36.1) 50 (4.3) 72 (42.6) 
Age (years)    
21 – 30 24 (39.3) 44 (40.7) 68 (40.2) 
31 – 40  16 (26.2) 30 (27.8) 46 (27.2) 
41 – 50  9 (14.8) 23 (21.3) 32 (18.9) 
51 – 60  8 (13.1) 10 (9.3) 18 (10.7) 
> 60 4 (6.56) 1 (0.9) 5 (3.0) 
Marital Status    
Married 50 (82) 81 (75) 131 (77.5) 
Single  11 (18) 27 (25) 38 (22.5) 
Qualification    
B.Sc./B. 
Pharm/Pharm D  
43 (70.5) 89 (82.3) 132 (78.1) 
Postgraduate 18 (29.5) 19 (17.6) 37 (22.0) 
Years of Practice    
1 – 5  14 (23) 23 (21.3) 37 (22.0) 
>6  37 (60.7) 95 (88) 132 (78) 
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Awareness of PV 61 (100) 108 (100) 169 (100) 
Trained 11 (18.0) 23 (21.3) 34 (20.1) 
Ability to define PV 32 (52.5) 79 (73.1) 111 (65.7) 
Knowing involves    
i. Monitoring ADRs 47 (77.0) 54 (50.0) 101 (59.8) 
ii. Reporting ADRs 53 (86.9) 90 (83.3) 143 (84.6) 
iii. Analysing ADRs 21 (34.4) 48 (44.4) 69 (40.8) 
Knowing those involved in PV    
i. Doctors 61 (100) 108 (100) 169 (100) 
ii. Pharmacists 56 (93.4) 102 (94.4) 158 (93.5) 
iii. Nurses/Midwives 54 (98.5) 108 (100)  
iv. Med Lab Scientists 28 (45.9) 76 (70.4) (104 (61.5) 
v. Patent Med Vendors 13 (21.3) 32 (29.6) 45 (26.6) 
vi. Herbal Med Practitioner 22 (36.1) 10 (9.3) 32 (18.9) 
vii. Other trained health 
workers 
37 (60.7) 66 (61.1) 103 (61.0) 
Types of Active PV    
i. CEM 25 (41.0) 68 (63.0) 93 (55.0) 
ii. PEM 20 (32.8) 36 (33.3) 56 (33.1) 
iii. IMMP 18 (30.0) 33 (30.6) 51 (30.2) 
Best definition of ADR 41 (67.2) 77 (71.3) 118 (68.8) 
Phase for detection of rare ADRs 
in clinical trial  
17 (27.7) 40 (37.0) 57 (33.7) 
Major risk factor for ADR to 
occur 
55 (90.2) 90 (83.3) 145 (85.8) 
Reason for withdrawal of 
Avandia 
36 (59.0) (80 (74.1) 116 (68.6) 
Reason for withdrawal of 
phenformin 
31 (50.8) 57 (52.8) 88 (52.1) 
Awareness of NAFDAC yellow 
form 
14 (23.0) 28 (26.0) 42 (24.9) 
CEM, cohort event monitoring; PEM, prescription event monitoring; IMMP, intensive medicines monitoring 




Figure 1: Percentages of pharmacists that responded “YES” to attitude related questions on key aspects of ADR 
reporting. Hospital pharmacists, N=61; Community pharmacists, N = 108 
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Figure 2: Pharmacists that responded to the attitude-related question of why ADRs were not reported. Hospital 




Figure 3: Pharmacists that responded to attitude related question of how reporting ADRs can affect their other 
professional responsibilities. Hospital pharmacists, N = 61; Community pharmacists, N = 108 
 
A number of factors accounted for poor reporting 
of ADRs but lack of time was the reason given by 
most community pharmacists (69.0%), while the 
excuse that one report coming from them was 
not sufficient to make impart was given by 63.0% 
of hospital pharmacists. Lack of incentive was 
the reason given by 26.6% of all the pharmacists. 
No reason was given by 35.0% of all pharmacists 
(Figure 2). 
 
In Figure 3, most pharmacists (77.5% of all) 
agreed that reporting ADR would give them self-
satisfaction and fewer pharmacists (33.1% of all) 
considered that it would result in more job stress. 
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The major considerations for hospital 
pharmacists were role overload (90.7%) and role 
conflict with other staff in the hospitals (82.5%). 
Out of all pharmacists 49.7% considered 




Practice of PV by pharmacists 
 
Regarding the practice related questions (Table 
3), 57.4% of community pharmacists and 82.4% 
of hospital pharmacists had encountered an ADR 
in the course of practice but only 26.2% of 
community pharmacists and 23.1% of hospital 
pharmacists had ever reported an ADR. This is in 
spite of the fact that 72.1% of community 
pharmacists and 88.0% of hospital pharmacists 
had seen an ADR reporting form. Altogether, 
24.3% of such reports were sent to NPC by the 
pharmacists. Very few community (13.1%) and 
hospital (16.7%) pharmacists could explain an 
approach to preventing ADR occurrence. The 
majority of respondents (87.6%) sourced their 
information on ADR from textbooks. 
 
Percentage scores of pharmacists on 
questions relating to KAP 
 
Hospital pharmacists had higher percentage 
scores for knowledge, attitude, and practice, than 
the community pharmacists (Table 4). 
 
Table 4: Percentage score on questions related to 
knowledge, attitude and practice by pharmacists in the 
two practice settings 
 
Variable Community Hospital 
Knowledge (24) 31.4 ± 17.8 58.9 ± 32.1 
Attitude (14) 30.2 ± 13.8 62.4 ± 28.4 




This study has shown that while all respondent 
pharmacists in the two states were aware of PV, 
only few had reported an ADR. The study also 
shows that not all pharmacists saw the need to 
report ADRs. The hospital pharmacists were 
superior to their community counterparts in KAP 
score. 
 
There was high awareness of the concept of 
pharmacovigilance (PV) by all pharmacists in the 
two States. The level of awareness of PV by 
hospital pharmacists was found to be low [18] 
and low level of awareness was reported for 
community pharmacists in Lagos State [20].The 
increase in awareness of the concept may be 
attributed to more recent regular broadcast of PV 
jingles by the National Agency for Food and Drug 
Administration and Control (NAFDAC) on news 
media. Although awareness was high among the 
 










Those who had seen an ADR  35 (57.4) 89 (82.4) 124 (73.4) 
 
Frequency of seeing ADRs 
   
i. Often 13 (21.3) 11 (10.2) 24 (14.2) 
ii. Regularly 7 (11.5) 31 (28.7) 38 (22.5) 
iii. Rarely 15 (24.6) 47 (43.5) 62 (36.7) 
iv. Never 26 (42.6) 19 (17.6) 45 (26.6) 
 













Suggestion to prevent ADRs 39 (63.9) 64 (59.3) 41 (24.3) 
Ability to explain suggestion 8 (13.1) 18 (16.7) 26 (15.4) 
 
Preference for ADR update 
   
i. Internet 28 (45.9) 63 (58.3) 91 (53.9) 
ii. Textbooks 57 (93.4) 91 (84.3) 148 (87.6) 
iii. Journals 18 (29.5) 27 (25.0) 45 (26.6) 
iv. Pharmaceutical sales reps 50 (82.0) 63 (58.3) 91 (53.9) 
v. Drug information leaflets 32 (52.5) 43 (39.8) 75 (44.4) 
vi. National PV newsletter 15 (24.6) 28 (25.9) 43 ( 25.4) 
 vii Others 36 (59.0) 55 (51) 91 (53.9) 
Total number of community pharmacists = 61; total number of hospital pharmacists = 108; NPC, National 
Pharmacovigilance Centre 
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pharmacists, the requisite knowledge required to 
participate effectively in PV activities seemed to 
be lacking. For example, not all pharmacists 
could define PV reasonably and about half of all 
the respondents did not know that cohort event 
monitoring is a type of active pharmacovigilance. 
Interestingly, only a small percentage of 
pharmacists had seen the individual case 
reporting form (ADR reporting form, Yellow 
Form) issued by the National Pharmacovigilance 
Centre (NPC) that is a unit of NAFDAC. 
Conversely, many more pharmacists in the two 
practice settings had seen an ADR reporting 
form which could have been the same NAFDAC 
form except that the colour was lost through 
photocopying. In comparative terms, hospital 
pharmacists were better knowledgeable than 
their community counterparts. This may be due 
to the fact that the hospital environment is more 
formal and drug safety committees, hospital 
formulary committees and clinical presentations 
often highlight the need for PV. 
 
The community pharmacy is often the first port of 
call by patients because of its ease of 
accessibility [10]. Therefore, it should be 
expected that cases of ADRs would be easily 
seen by practitioners who should then report 
them to the NPC. This study has shown that 
although a high percentage of community 
pharmacists saw the need to report ADRs, they 
complained of lack of time. It seems that 
community pharmacists considered other 
aspects of practice and sales turnover higher 
than reporting of ADRs. A similar study has 
shown that 50% of hospital and community 
pharmacists in a province of South Africa 
considered reporting to be time consuming [23]. 
The time factor may explain why 47.5 % of 
community pharmacists as against 72 % of 
hospital pharmacists suggested that reporting 
ADRs should be mandatory if success is to be 
attained. Interestingly, all the pharmacists 
believed that participating in PV activities could 
enhance job satisfaction. Despite this, issues 
such as job overload, role conflict and role 
ambiguity are potential factors that could 
negatively influence participation in PV 
particularly among hospital pharmacists. For 
example, incidences of role conflict between 
pharmacists and doctors have been reported 
[24]. Lack of communication has been identified 
as a cause of poor doctors-pharmacists working 
relationship that inter-professional education 
could solve [25]. Although it is considered 
important [26], pharmacists in the two practice 
settings did not consider giving incentives a 
major stimulus for ADR reporting. That 33.3 % of 
hospital pharmacists and 39.3 % of community 
pharmacists did not have reasons for not 
reporting ADRs underscores the poor attitude 
towards PV that should be addressed. 
 
The practice of PV is low by both hospitals and 
community pharmacists as only 23.1% and 
26.2% respectively had ever reported an ADR. 
This is not consistent with the high numbers of 
pharmacists in the two practice settings that had 
seen an ADR in practice. Low level of reporting 
has also been reported by others [20,27]. The 
poor attitude to PV earlier highlighted may 
explain why only few pharmacists had reported 
ADRs in spite of the fact that ADR reporting 
forms can be downloaded from NAFDAC 
website. 
 
This study also shows a worrisome trend in the 
referencing sources for ADRs as most of the 
pharmacists updated their knowledge from 
textbooks. It is generally known that textbooks 
are usually not very current with information on 
drugs [28]. This may be due to the time lag 
between assemblage of manuscripts and 
eventual publishing of the textbook. A high 
percentage of the community pharmacists 
(82.0%) also depended on pharmaceutical sales 
representatives for their information on ADRs. 
Representatives of companies may not always 
be balanced in the information that they give 
about their products [29]. In addition, acceptance 
of promotional items from representatives could 
result in failure of pharmacists to report ADRs 
associated with the companies [30]. 
 
In a study in India, training was found to correlate 
positively with pharmacovigilance activities by 
health workers [31].In order for professionals to 
be good signal generators, it is important to train 
and re-train them on safety issues with particular 
reference to the drugs that are commonly used in 
practice[32].Qualifications in terms of additional 
degrees obtained after the basic B.Pharm or 
PharmD degree is similar to further training and 
the curricular for postgraduate programmes often 
contain PV related topics. Therefore continuous 
informal training and acquisition of postgraduate 
qualification may be used to address the flaws in 




Although there was a high level of awareness of 
PV by pharmacists in the two South-Eastern 
States of Nigeria, the attitude and practice 
through ADR reporting were very poor. This 
implies that measures such as making reporting 
form available to all pharmacists and 
continuously reminding them through meetings 
and lectures, that reporting ADRs is ethical and 
mandatory should be taken. This will further 
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strengthen drug safety in the two states. The 
major limitations to the study include the non-
evaluation of the quality of ADR reported by the 
few pharmacists and the inability of the 
investigators to review patient charts to ascertain 
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